Latest Conference Articles

The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.

There is no clear threshold for consumption leading to an AFib event.

Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

The 1-year follow-up of the REALITY trial presented at ACC undermines previously reported 30-day findings showing noninferiority to liberal transfusions.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

A post-hoc analysis sought to elucidate the contradictory results between the STRENGTH and REDUCE-IT trials.

Older patients who maintained the multi-domain rehabilitation program saw improvements in various markers of physical function.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Improvements in patient symptoms, function, and quality of life were not sustained once treatment was discontinued.

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

Data suggests that the non-vitamin K antagonist blood thinner may be used as default treatment among post-operative patients in need of oral anticoagulation.

A new study presented at ASGCT found that patients with indications of hemostatic efficacy experienced few adverse effects with gene therapy treatment BAY 2599023.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.

Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.

Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.

The implant was linked to visual acuity improvements at final follow-up visit.

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.

Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.